Skip to main content
Fig. 5 | Journal of Experimental & Clinical Cancer Research

Fig. 5

From: The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer

Fig. 5

Effects of CUDC-907 and olaparib on the DNA repair pathways. a Representative images of Rad51 immunofluorescence staining in SCLC cells treated with drugs as indicated for 24 h. Scale bar, 10 μm. Quantification of Rad51 fluorescence intensities from three independent experiments was shown in right panels. b, c Western blot analysis of DDR proteins (b) and MYC paralogs and FoxM1 (c) in SCLC cells followed 10 nM CUDC-907 and 10 μM olaparib as single-agents or in combination treatment for 24 h. The antibody against MYCN was used to detect MYCN in H526 and H69 and anti-c-MYC was applied for the detection of c-MYC in rest of cell lines, β-actin was used as a loading control

Back to article page